Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated warning statement is fully supported by the provided SOVALDI FDA label, including HBV reactivation risk in HCV/HBV coinfection (including resolved HBV), severe outcomes, and instructions for HBV testing prior to therapy and monitoring during and after treatment, plus patient counseling.
Category Scores
Accurate Statements
SOVALDI warns that HBV reactivation can occur in patients coinfected with HCV and HBV (including resolved HBV), with potential for severe outcomes.
Supported by label section 5.1: HBV reactivation reported in HCV/HBV coinfected patients undergoing or completing HCV direct-acting antiviral therapy; includes HBsAg-positive and resolved infection (HBsAg negative/anti-HBc positive); severe outcomes described (fulminant hepatitis, hepatic failure, death).
Patients should be tested for HBV before starting SOVALDI.
Supported by label sections 2.1 and 5.1: test all patients for current or prior HBV infection using HBsAg and anti-HBc before initiating HCV treatment with SOVALDI.
Patients should be monitored during and after treatment.
Supported by label section 5.1: in patients with serologic evidence of HBV infection, monitor for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV treatment with SOVALDI and during post-treatment follow-up.
Patient counseling should include that HBV reactivation can occur during or after treatment and patients should disclose a history of HBV infection.
Supported by label section 17: inform patients HBV reactivation can occur during or after treatment and advise patients to tell their healthcare provider if they have a history of HBV infection.
Unsupported Statements
Contradictions
Important Omissions
The AI statement does not explicitly mention that HBV reactivation risk may be increased in patients receiving certain immunosuppressant or chemotherapeutic agents while on HCV direct-acting antiviral treatment.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The key warning elements from the label (HBV reactivation risk in coinfection including resolved HBV, severe outcomes, pre-treatment HBV testing, and monitoring during and after therapy) are accurately conveyed. The only omission is the label’s added note about increased risk with certain immunosuppressant/chemotherapeutic agents, which is not central to the primary safety workflow described.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: does not mention increased risk in patients receiving certain immunosuppressant or chemotherapeutic agents.
Suggested Improvement
Add that the label notes HBV reactivation risk associated with HCV direct-acting antivirals may be increased in patients receiving certain immunosuppressant or chemotherapeutic agents.